PBC patients receiving linerixibat saw statistically significant improvement in cholestatic pruritus - or relentless itch.

GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...

Intercept said it will work with the FDA on next steps, and the drug remains on the market. PBC is a rare and chronic liver ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...

GSK plc GSK announced positive headline data from the phase III GLISTEN study, which is evaluating its investigational ...

Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use ...